Table of Contents PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOR MULTIPLE MYELOMA: AN INSIGHT • Introduction PART 05: MAJOR REGULATORY AUTHORITIES • US • Europe • Japan • Australia • China PART 06: PIPELINE LANDSCAPE PART 07: COMPARATIVE ANALYSIS • Mid-stage molecules (Phase II and I/II) • Early-stage molecules (Phase I and IND) • Pre-clinical and discovery-stage molecules PART 08: INDICATION ANALYSIS PART 09: THERAPEUTIC ASSESSMENT BY THERAPY • Therapeutic assessment based on therapy PART 10: THERAPEUTIC ASSESSMENT BY ROA • Therapeutic assessment based on RoA PART 11: THERAPEUTIC ASSESSMENT BY TARGET PART 12: KEY COMPANIES • Active companies: Category and parameters PART 13: APPENDIX • List of abbreviations List of Exhibits Exhibit 01: Drug approval process by US FDA Exhibit 02: Pipeline molecules by vendors Exhibit 03: Pipeline landscape Exhibit 04: Pipeline molecules by numbers Exhibit 05: Pipeline molecules by percentage Exhibit 06: Overview: Tisagenlecleucel-T Exhibit 07: Clinical Trials Description of Tisagenlecleucel-T (CTL019 T-cells) Exhibit 08: Overview: LCAR-B38M Exhibit 09: Clinical trials description Exhibit 10: Overview: AUTO2 Exhibit 11: Clinical trials description of AUTO2 Exhibit 12: P-BCMA-101: Overview Exhibit 13: Overview: CAR-T NKR-2 Exhibit 14: Clinical trials description of CAR-T NKR-2 Exhibit 15: Overview: CM-CS1 Exhibit 16: Clinical trials description of CM-CS1 Exhibit 17: Overview: EGFRt/BCMA-41BBz CAR T-cell Exhibit 18: Clinical trials description of EGFRt/BCMA-41BBz CAR T-cell Exhibit 19: Overview: bb2121 Exhibit 20: Clinical trials description of bb2121 Exhibit 21: Overview: KITE-585 Exhibit 22: Overview: T-007 Exhibit 23: Overview: KMA.CAR-T Exhibit 24: Overview: MB-104 CS1 CAR Exhibit 25: Overview: Compound CAR Exhibit 26: Overview: UCART38 Exhibit 27: Overview: UCARTCS1 Exhibit 28: Overview: LMA.CAR-T Exhibit 29: Analysis by indication Exhibit 30: Overview of indication Exhibit 31: Assessment of pipeline products by therapy Exhibit 32: Assessment by RoA Exhibit 33: Assessment by target Exhibit 34: Percentage of the company for different tier category Exhibit 35: Overview: Autolus 2017 Exhibit 36: Overview: bluebird bio 2017 Exhibit 37: Overview: Celyad 2016 Exhibit 38: Overview: Cellectis 2016 Exhibit 39: Overview: HaemaLogiX 2017 Exhibit 40: Overview: iCell Gene Therapeutics 2017 Exhibit 41: Overview: Juno Therapeutics 2017 Exhibit 42: Overview: Kite Pharma 2017 Exhibit 43: Overview: Mustang Bio 2017 Exhibit 44: Overview: Nanjing Legend Biotech 2017 Exhibit 45: Overview: Novartis 2017 Exhibit 46: Overview: Poseida 2017 Exhibit 47: Overview: TNK Therapeutics 2016

Juno Therapeutics, Kite Pharma, Novartis, and Collectis.